Keebeck Wealth Management Acquires New Stake in Medpace Holdings, Inc. $MEDP

Keebeck Wealth Management acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,199 shares of the company’s stock, valued at approximately $635,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. BlackRock Inc. purchased a new stake in shares of Medpace during the second quarter worth $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Madison Asset Management LLC purchased a new position in shares of Medpace in the second quarter worth about $128,956,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Up 1.3%

NASDAQ MEDP opened at $620.75 on Friday. The business’s fifty day simple moving average is $550.16 and its 200-day simple moving average is $492.71. The firm has a market cap of $17.33 billion, a PE ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $584.18.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 122,261 shares of company stock worth $71,729,129 over the last ninety days. 20.50% of the stock is currently owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.